Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

17 Apr 2019

Abstract excerpt

Eradicating triple-negative breast cancer (TNBC) resistant to neoadjuvant chemotherapy (NACT) is a critical unmet clinical need. In this study, patient-derived xenograft (PDX) models of treatment-naïve TNBC and serial biopsies from TNBC patients undergoing NACT were used to elucidate mechanisms of chemoresistance in the neoadjuvant setting. Barcode-mediated clonal tracking and genomic sequencing of PDX tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30996079
DOI: 10.1126/scitranslmed.aav0936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant statePMID 30996079Read ↗

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapySemantic proximity Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.Semantic proximity Read ↗

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity Read ↗

Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast Cancer by Single-Cell Transcriptomic AnalysisSemantic proximity Read ↗

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.Semantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.Semantic proximity Read ↗

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.Semantic proximity Read ↗

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerSemantic proximity Read ↗

Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistanceSemantic proximity Read ↗

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.